116th CONGRESS 1st Session S

To amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009.

IN THE SENATE OF THE UNITED STATES

Ms. SMITH introduced the following bill; which was read twice and referred to the Committee on

A BILL

- To amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009.
 - 1 Be it enacted by the Senate and House of Representa-
 - 2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the "Protecting Access to5 Biosimilars Act of 2019".

2

| 1 | SEC. 2. TREATMENT OF BIOLOGICAL PRODUCTS DEEMED |
|----|--|
| 2 | LICENSED. |
| 3 | Section $351(k)(7)$ of the Public Health Service Act |
| 4 | (42 U.S.C. $262(k)(7)$) is amended by adding at the end |
| 5 | the following: |
| 6 | "(D) DEEMED LICENSES.— |
| 7 | "(i) NO ADDITIONAL EXCLUSIVITY |
| 8 | THROUGH DEEMING.—An approved appli- |
| 9 | cation that is deemed to be a license for a |
| 10 | biological product under this section pursu- |
| 11 | ant to section $7002(e)(4)$ of the Biologics |
| 12 | Price Competition and Innovation Act of |
| 13 | 2009 shall not be treated as having been |
| 14 | first licensed under subsection (a) for pur- |
| 15 | poses of subparagraphs (A) and (B). |
| 16 | "(ii) LIMITATION ON EXCLUSIVITY AP- |
| 17 | PLIES TO ANY REFERENCE PRODUCT.— |
| 18 | Subparagraph (C) shall apply to any ref- |
| 19 | erence product, without regard to wheth- |
| 20 | er— |
| 21 | "(I) such product was first li- |
| 22 | censed under subsection (a); or |
| 23 | "(II) the approved application for |
| 24 | such product was deemed to be a li- |
| 25 | cense for a biological product as de- |
| 26 | scribed in clause (i).". |